How were the genomic tests in SYMPHONY discovered?

As published in Nature, the SYMPHONY genomic profile was developed by taking samples from a population of thousands untreated breast cancer tumors whose 10 year outcome was known. Using these untreated breast cancer tumors, they looked at all 25,000 human genes in order to learn which ones are involved in breast cancer metastasis. Researchers were able to separate the tumors into two categories: those tumors that came back and those tumors that did not recur within 10 years. By comparing the gene expression of the two groups of tumor cells, they were able to identify the most prognostic genes involved in breast cancer. A precise bioinformatics algorithm was used to determine the 70 gene expression signature that clearly and accurately identified those tumors that would likely recur in 10 years and those that would not.

 

MammaPrint is the only gene expression profile cleared by the FDA to assess the individual risk of breast cancer metastasis. As a truly “next generation” diagnostic test, MammaPrint takes advantage of the progress made by the Human Genome Project and recent advances in multigene microarray technology to analyze the complex biology of a tumor and provide you and your clinician with detailed information about your cancer.

Genome Investigation Pty Ltd

This new Australian company commenced activity in 2013 with the aim of bringing MammaPrint and BluePrint technology to Australian women. Based in New South Wales, Genome Investigation Pty Ltd is committed to the rapid transportation of breast cancer tissue of affected women from Australian pathology laboratories to the Agendia Laboratory in California, USA, to ensure a quick turn around reporting time is made possible (usually under 2 weeks).